{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:54:51Z","timestamp":1793055291238,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Ribosomal protein L5 (RPL5) is considered a haplo-insufficient tumor suppressor by upregulating p53 expression or promoting the inactivation of c-Myc in solid tumors upon tumor initiation. However, its detailed effect and mechanism in tumor maintenance were more complicated. Particularly, the specific role of RPL5 in acute myeloid leukemia (AML) remains unclear. In this study, we found that RPL5 expression was increased in primary AML blasts compared with normal controls, regardless of\n                    <jats:italic>TP53<\/jats:italic>\n                    mutation. RPL5 knockdown reduced the survival and colony-forming ability of AML cells in vitro, as well as inhibited the engraftment of leukemia stem cells (LSCs) in vivo. It indicated that RPL5 was required for the survival of AML cells, especially for maintaining the stemness of LSCs. The data analysis of RNA-seq and proteomics revealed that RPL5 deficiency eradicated LSC by inducing a cellular stress response, i.e., ribosomal stress, rather than a specific function relating to RPL5. The inhibited PI3K-Akt-mTOR signaling pathway played a central role in the ribosomal stress induced by RPL5 deficiency. To investigate the selectivity of RPL5 depletion in eradicating LSCs, we found that RPL5 expression was highest in LSCs compared to AML cells and healthy controls. Moreover, ribosomal stress specifically affected transcripts with longer exon lengths and proteins with a lower isoleucine (Ile) to valine (Val) ratio. Ile and Val are glycogenic branched-chain amino acids (BCAAs) that regulate fundamental cell processes by affecting mTOR activation through BCAA metabolism. In conclusion, RPL5 depletion-induced ribosomal stress disrupted stemness maintenance by affecting BCAA metabolism in AML, specifically inhibiting the PI3K-Akt-mTOR signaling pathway, which resulted in LSC eradication.\n                  <\/jats:p>","DOI":"10.1038\/s41419-025-08379-1","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T04:27:18Z","timestamp":1766032038000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["RPL5 deficiency-induced ribosomal stress targets a select subset of proteins and inhibits the PI3K-Akt-mTOR signaling pathway to eradicate leukemia stem cells"],"prefix":"10.1038","volume":"17","author":[{"given":"Xiaofei","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daijiao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gangfeng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqian","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuzhi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanyu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongyun","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1223-4325","authenticated-orcid":false,"given":"Shenmeng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"8379_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136\u201352.","journal-title":"N Engl J Med"},{"key":"8379_CR2","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1038\/s41388-020-1179-6","volume":"39","author":"Y Li","year":"2020","unstructured":"Li Y, Zhou Y, Li B, Chen F, Shen W, Lu Y, et al. WDR74 modulates melanoma tumorigenesis and metastasis through the RPL5\u2013MDM2\u2013p53 pathway. Oncogene. 2020;39:2741\u201355.","journal-title":"Oncogene"},{"key":"8379_CR3","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/bjh.17746","volume":"196","author":"S Kayser","year":"2022","unstructured":"Kayser S, Levis MJ. Updates on targeted therapies for acute myeloid leukaemia. Br J Haematol. 2022;196:316\u201328.","journal-title":"Br J Haematol"},{"key":"8379_CR4","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/ajh.25620","volume":"94","author":"M Molica","year":"2019","unstructured":"Molica M, Breccia M, Foa R, Jabbour E, Kadia TM. Maintenance therapy in AML: the past, the present and the future. Am J Hematol. 2019;94:1254\u201365.","journal-title":"Am J Hematol"},{"key":"8379_CR5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","volume":"21","author":"F Thol","year":"2020","unstructured":"Thol F, Ganser A. Treatment of relapsed acute myeloid leukemia. Curr Treat Options Oncol. 2020;21:66.","journal-title":"Curr Treat Options Oncol"},{"key":"8379_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41568-019-0230-9","volume":"20","author":"D Vetrie","year":"2020","unstructured":"Vetrie D, Helgason GV, Copland M. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nat Rev Cancer. 2020;20:158\u201373.","journal-title":"Nat Rev Cancer"},{"key":"8379_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1756-8722-5-32","volume":"5","author":"N Shenoy","year":"2012","unstructured":"Shenoy N, Kessel R, Bhagat TD, Bhattacharyya S, Yu Y, McMahon C, et al. Alterations in the ribosomal machinery in cancer and hematologic disorders. J Hematol Oncol. 2012;5:32.","journal-title":"J Hematol Oncol"},{"key":"8379_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrc.2017.104","volume":"18","author":"J Pelletier","year":"2018","unstructured":"Pelletier J, Thomas G, Volarevi\u0107 S. Ribosome biogenesis in cancer: new players and therapeutic avenues. Nat Rev Cancer. 2018;18:51\u201363.","journal-title":"Nat Rev Cancer"},{"key":"8379_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03531-2","volume":"9","author":"J Wu","year":"2018","unstructured":"Wu J, Jiang X, Li Y, Zhu T, Zhang J, Zhang Z, et al. PHA-4\/FoxA senses nucleolar stress to regulate lipid accumulation in Caenorhabditis elegans. Nat Commun. 2018;9:1195.","journal-title":"Nat Commun"},{"key":"8379_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41392-021-00728-8","volume":"6","author":"J Kang","year":"2021","unstructured":"Kang J, Brajanovski N, Chan KT, Xuan J, Pearson RB, Sanij E. Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy. Signal Transduct Target Ther. 2021;6:323.","journal-title":"Signal Transduct Target Ther"},{"key":"8379_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.821366","volume":"12","author":"T Han","year":"2022","unstructured":"Han T, Tong J, Wang M, Gan Y, Gao B, Chen J, et al. Olaparib induces RPL5\/RPL11-dependent p53 activation via nucleolar stress. Front Oncol. 2022;12:821366.","journal-title":"Front Oncol"},{"key":"8379_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1756-9966-28-6","volume":"28","author":"M Wang","year":"2009","unstructured":"Wang M, Hu Y, Stearns ME. RPS2: a novel therapeutic target in prostate cancer. J Exp Clin Cancer Res. 2009;28:6.","journal-title":"J Exp Clin Cancer Res"},{"key":"8379_CR13","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1158\/1078-0432.CCR-05-2445","volume":"12","author":"A Bee","year":"2006","unstructured":"Bee A, Ke Y, Forootan S, Lin K, Beesley C, Forrest SE, et al. Ribosomal protein l19 is a prognostic marker for human prostate cancer. Clin Cancer Res. 2006;12:2061\u20135.","journal-title":"Clin Cancer Res"},{"key":"8379_CR14","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.3892\/ijo.2016.3387","volume":"48","author":"KM Goudarzi","year":"2016","unstructured":"Goudarzi KM, Lindstrom MS. Role of ribosomal protein mutations in tumor development (Review). Int J Oncol. 2016;48:1313\u201324.","journal-title":"Int J Oncol"},{"key":"8379_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06660-w","volume":"9","author":"M Thoms","year":"2018","unstructured":"Thoms M, Mitterer V, Kater L, Falquet L, Beckmann R, Kressler D, et al. Suppressor mutations in Rpf2-Rrs1 or Rpl5 bypass the Cgr1 function for pre-ribosomal 5S RNP-rotation. Nat Commun. 2018;9:4094.","journal-title":"Nat Commun"},{"key":"8379_CR16","doi-asserted-by":"publisher","first-page":"14462","DOI":"10.18632\/oncotarget.14895","volume":"8","author":"L Fancello","year":"2017","unstructured":"Fancello L, Kampen KR, Hofman IJ, Verbeeck J, De Keersmaecker K. The ribosomal protein gene RPL5 is a haploinsufficient tumor suppressor in multiple cancer types. Oncotarget. 2017;8:14462\u201378.","journal-title":"Oncotarget"},{"key":"8379_CR17","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3390\/cancers13050951","volume":"13","author":"P Robak","year":"2021","unstructured":"Robak P, Jarych D, Mikulski D, Drozdz I, Weglowska E, Kotkowska A, et al. The prognostic value of whole-blood PSMB5, CXCR4, POMP, and RPL5 mRNA expression in patients with multiple myeloma treated with bortezomib. Cancers. 2021;13:951.","journal-title":"Cancers"},{"key":"8379_CR18","doi-asserted-by":"publisher","first-page":"4660","DOI":"10.1128\/MCB.01174-13","volume":"33","author":"T Teng","year":"2013","unstructured":"Teng T, Mercer CA, Hexley P, Thomas G, Fumagalli S. Loss of tumor suppressor RPL5\/RPL11 does not induce cell cycle arrest but impedes proliferation due to reduced ribosome content and translation capacity. Mol Cell Biol. 2013;33:4660\u201371.","journal-title":"Mol Cell Biol"},{"key":"8379_CR19","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/leu.2016.370","volume":"31","author":"IJF Hofman","year":"2016","unstructured":"Hofman IJF, van Duin M, De Bruyne E, Fancello L, Mulligan G, Geerdens E, et al. RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response. Leukemia. 2016;31:1706\u201314.","journal-title":"Leukemia"},{"key":"8379_CR20","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/pin.13168","volume":"71","author":"Y Fukui","year":"2021","unstructured":"Fukui Y, Hayano S, Kawanabe N, Wang Z, Shimada A, Saito MK, et al. Investigation of the molecular causes underlying physical abnormalities in Diamond-Blackfan anemia patients with RPL5 haploinsufficiency. Pathol Int. 2021;71:803\u201313.","journal-title":"Pathol Int"},{"key":"8379_CR21","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/nature04980","volume":"442","author":"AV Krivtsov","year":"2006","unstructured":"Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442:818\u201322.","journal-title":"Nature"},{"key":"8379_CR22","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jim.2009.06.008","volume":"347","author":"Y Hu","year":"2009","unstructured":"Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol methods. 2009;347:70\u20138.","journal-title":"J Immunol methods"},{"key":"8379_CR23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ccr.2006.08.020","volume":"10","author":"TC Somervaille","year":"2006","unstructured":"Somervaille TC, Cleary ML. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell. 2006;10:257\u201368.","journal-title":"Cancer Cell"},{"key":"8379_CR24","doi-asserted-by":"publisher","first-page":"7980","DOI":"10.3390\/molecules16097980","volume":"16","author":"BL Cavanagh","year":"2011","unstructured":"Cavanagh BL, Walker T, Norazit A, Meedeniya AC. Thymidine analogues for tracking DNA synthesis. Molecules. 2011;16:7980\u201393.","journal-title":"Molecules"},{"key":"8379_CR25","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1182\/blood-2003-02-0578","volume":"102","author":"T Yagi","year":"2003","unstructured":"Yagi T, Morimoto A, Eguchi M, Hibi S, Sako M, Ishii E, et al. Identification of a gene expression signature associated with pediatric AML prognosis. Blood. 2003;102:1849\u201356.","journal-title":"Blood"},{"key":"8379_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/gcc.20500","volume":"47","author":"DL Stirewalt","year":"2008","unstructured":"Stirewalt DL, Meshinchi S, Kopecky KJ, Fan W, Pogosova-Agadjanyan EL, Engel JH, et al. Identification of genes with abnormal expression changes in acute myeloid leukemia. Genes Chromosomes Cancer. 2008;47:8\u201320.","journal-title":"Genes Chromosomes Cancer"},{"key":"8379_CR27","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/j.1365-2141.2008.07261.x","volume":"142","author":"A Kohlmann","year":"2008","unstructured":"Kohlmann A, Kipps TJ, Rassenti LZ, Downing JR, Shurtleff SA, Mills KI, et al. An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in Leukemia study prephase. Br J Haematol. 2008;142:802\u20137.","journal-title":"Br J Haematol"},{"key":"8379_CR28","doi-asserted-by":"publisher","first-page":"18626","DOI":"10.1073\/pnas.1311100110","volume":"110","author":"H Hosokawa","year":"2013","unstructured":"Hosokawa H, Tanaka T, Kato M, Shinoda K, Tohyama H, Hanazawa A, et al. Gata3\/Ruvbl2 complex regulates T helper 2 cell proliferation via repression of Cdkn2c expression. Proc Natl Acad Sci USA. 2013;110:18626\u201331.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8379_CR29","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1278081","volume":"2017","author":"M Liu","year":"2017","unstructured":"Liu M, Xu Z, Du Z, Wu B, Jin T, Xu K, et al. The identification of key genes and pathways in glioma by bioinformatics analysis. J Immunol Res. 2017;2017:1278081.","journal-title":"J Immunol Res"},{"key":"8379_CR30","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1080\/15384101.2017.1403685","volume":"17","author":"Z Turi","year":"2018","unstructured":"Turi Z, Senkyrikova M, Mistrik M, Bartek J, Moudry P. Perturbation of RNA polymerase I transcription machinery by ablation of HEATR1 triggers the RPL5\/RPL11-MDM2-p53 ribosome biogenesis stress checkpoint pathway in human cells. Cell Cycle. 2018;17:92\u2013101.","journal-title":"Cell Cycle"},{"key":"8379_CR31","doi-asserted-by":"publisher","first-page":"4916","DOI":"10.1038\/onc.2013.430","volume":"33","author":"JM Liao","year":"2014","unstructured":"Liao JM, Zhou X, Gatignol A, Lu H. Ribosomal proteins L5 and L11 co-operatively inactivate c-Myc via RNA-induced silencing complex. Oncogene. 2014;33:4916\u201323.","journal-title":"Oncogene"},{"key":"8379_CR32","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cell.2020.06.006","volume":"182","author":"CC Wu","year":"2020","unstructured":"Wu CC, Peterson A, Zinshteyn B, Regot S, Green R. Ribosome collisions trigger general stress responses to regulate cell fate. Cell. 2020;182:404\u201316 e14.","journal-title":"Cell"},{"key":"8379_CR33","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cbi.2017.08.011","volume":"277","author":"Z Lu","year":"2017","unstructured":"Lu Z, Miao Y, Muhammad I, Tian E, Hu W, Wang J, et al. Colistin-induced autophagy and apoptosis involves the JNK-Bcl2-Bax signaling pathway and JNK-p53-ROS positive feedback loop in PC-12 cells. Chem Biol Interact. 2017;277:62\u201373.","journal-title":"Chem Biol Interact"},{"key":"8379_CR34","doi-asserted-by":"publisher","first-page":"10648","DOI":"10.1093\/nar\/gkaa757","volume":"48","author":"AC Vind","year":"2020","unstructured":"Vind AC, Genzor AV, Bekker-Jensen S. Ribosomal stress-surveillance: three pathways is a magic number. Nucleic Acids Res. 2020;48:10648\u201361.","journal-title":"Nucleic Acids Res"},{"key":"8379_CR35","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.febslet.2014.03.024","volume":"588","author":"J Armistead","year":"2014","unstructured":"Armistead J, Triggs-Raine B. Diverse diseases from a ubiquitous process: the ribosomopathy paradox. FEBS Lett. 2014;588:1491\u2013500.","journal-title":"FEBS Lett"},{"key":"8379_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-981-13-7342-8_1","volume":"1143","author":"LM Gurska","year":"2019","unstructured":"Gurska LM, Ames K, Gritsman K. Signaling pathways in leukemic stem cells. Adv Exp Med Biol. 2019;1143:1\u201339.","journal-title":"Adv Exp Med Biol"},{"key":"8379_CR37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","volume":"8","author":"ME Bahar","year":"2023","unstructured":"Bahar ME, Kim HJ, Kim DR. Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther. 2023;8:455.","journal-title":"Signal Transduct Target Ther"},{"key":"8379_CR38","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.cell.2018.02.036","volume":"173","author":"RK Khajuria","year":"2018","unstructured":"Khajuria RK, Munschauer M, Ulirsch JC, Fiorini C, Ludwig LS, McFarland SK, et al. Ribosome levels selectively regulate translation and lineage commitment in human hematopoiesis. Cell. 2018;173:90\u2013103.e19.","journal-title":"Cell"},{"key":"8379_CR39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/molecules30010056","volume":"30","author":"T Bo","year":"2024","unstructured":"Bo T, Fujii J. Primary roles of branched chain amino acids (BCAAs) and their metabolism in physiology and metabolic disorders. Molecules. 2024;30:56.","journal-title":"Molecules"},{"key":"8379_CR40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40104-016-0139-z","volume":"8","author":"S Zhang","year":"2017","unstructured":"Zhang S, Zeng X, Ren M, Mao X, Qiao S. Novel metabolic and physiological functions of branched chain amino acids: a review. J Anim Sci Biotechnol. 2017;8:10.","journal-title":"J Anim Sci Biotechnol"},{"key":"8379_CR41","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1182\/blood.2021011846","volume":"139","author":"MF O\u2019Donohue","year":"2022","unstructured":"O\u2019Donohue MF, Da Costa L, Lezzerini M, Unal S, Joret C, Bartels M, et al. HEATR3 variants impair nuclear import of uL18 (RPL5) and drive Diamond-Blackfan anemia. Blood. 2022;139:3111\u201326.","journal-title":"Blood"},{"key":"8379_CR42","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.3390\/ijms21082907","volume":"21","author":"I Nepstad","year":"2020","unstructured":"Nepstad I, Hatfield KJ, Gr\u00f8nnings\u00e6ter IS, Reikvam H. The PI3K-Akt-mTOR signaling pathway in human acute myeloid leukemia (AML) cells. Int J Mol Sci. 2020;21:2907.","journal-title":"Int J Mol Sci"},{"key":"8379_CR43","doi-asserted-by":"publisher","first-page":"e31275","DOI":"10.7554\/eLife.31275","volume":"7","author":"Z Fang","year":"2018","unstructured":"Fang Z, Cao B, Liao JM, Deng J, Plummer KD, Liao P, et al. SPIN1 promotes tumorigenesis by blocking the uL18 (universal large ribosomal subunit protein 18)-MDM2-p53 pathway in human cancer. Elife. 2018;7:e31275.","journal-title":"Elife"},{"key":"8379_CR44","doi-asserted-by":"publisher","first-page":"12018","DOI":"10.1074\/jbc.C117.794982","volume":"292","author":"XX Wang","year":"2017","unstructured":"Wang XX, Luo Y, Wang D, Adorini L, Pruzanski M, Dobrinskikh E, et al. A dual agonist of farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice. J Biol Chem. 2017;292:12018\u201324.","journal-title":"J Biol Chem"},{"key":"8379_CR45","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.stem.2018.05.003","volume":"22","author":"C Baumgartner","year":"2018","unstructured":"Baumgartner C, Toifl S, Farlik M, Halbritter F, Scheicher R, Fischer I, et al. An ERK-dependent feedback mechanism prevents hematopoietic stem cell exhaustion. Cell Stem Cell. 2018;22:879\u201392.e6.","journal-title":"Cell Stem Cell"},{"key":"8379_CR46","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41375-022-01798-5","volume":"37","author":"NR Anderson","year":"2023","unstructured":"Anderson NR, Sheth V, Li H, Harris MW, Qiu S, Crossman DK, et al. Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling. Leukemia. 2023;37:560\u201370.","journal-title":"Leukemia"},{"key":"8379_CR47","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1159\/000527456","volume":"146","author":"L Zhou","year":"2023","unstructured":"Zhou L, Shan Z, Fan J. Extracellular vesicles derived from human bone marrow stem cells inhibit acute lymphoblastic leukemia cell growth by inhibiting mapk pathway via the miR-29b-3p\/GDF15 axis. Acta Haematol. 2023;146:504\u201316.","journal-title":"Acta Haematol"},{"key":"8379_CR48","doi-asserted-by":"publisher","first-page":"4446","DOI":"10.1021\/acs.jafc.1c00726","volume":"69","author":"X Zhu","year":"2021","unstructured":"Zhu X, Wang W, Cui C. Hypoglycemic effect of hydrophobic BCAA peptides is associated with altered PI3K\/Akt protein expression. J Agric Food Chem. 2021;69:4446\u201352.","journal-title":"J Agric Food Chem"},{"key":"8379_CR49","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature10912","volume":"485","author":"AC Hsieh","year":"2012","unstructured":"Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 2012;485:55\u201361.","journal-title":"Nature"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08379-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08379-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08379-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T18:02:27Z","timestamp":1769536947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08379-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8379"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08379-1","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"2 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures followed the Declaration of Helsinki and the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University. Both AML patients and healthy volunteers have provided informed consent according to the declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read the manuscript and consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"117"}}